OpenAI acquires Orchestra Bio to advance AI drug development

researchDigiTimesOct 22, 2026

OpenAI has acquired biotech startup Orchestra Bio and will integrate its team and technology into its life sciences research platform, Rosalind, expanding AI applications in drug development in an effort to accelerate the arrival of new therapies.

Impact: LowConfidence: MediumNovelty: Incremental
researchdigitimes

See the whole story

Read the original on DigiTimes

Sens.ai aggregates and assesses published reporting. The assessment above is machine generated; the original source is authoritative.